Rapid Therapeutic Science Laboratories, Inc. (RTSL) Net Cash Flow (2016 - 2023)
Rapid Therapeutic Science Laboratories' Net Cash Flow history spans 8 years, with the latest figure at -$15412.0 for Q2 2023.
- For Q2 2023, Net Cash Flow fell 119.46% year-over-year to -$15412.0; the TTM value through Jun 2023 reached -$110004.0, down 271.22%, while the annual FY2022 figure was -$192484.0, 37.23% up from the prior year.
- Net Cash Flow for Q2 2023 was -$15412.0 at Rapid Therapeutic Science Laboratories, down from $17572.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $871789.0 in Q3 2021 and bottomed at -$727223.0 in Q4 2021.
- The 5-year median for Net Cash Flow is $1132.0 (2019), against an average of -$10168.8.
- The largest annual shift saw Net Cash Flow soared 6693.99% in 2020 before it crashed 2934.26% in 2021.
- A 5-year view of Net Cash Flow shows it stood at $121872.0 in 2019, then increased by 15.63% to $140923.0 in 2020, then tumbled by 616.04% to -$727223.0 in 2021, then skyrocketed by 84.58% to -$112164.0 in 2022, then soared by 86.26% to -$15412.0 in 2023.
- Per Business Quant, the three most recent readings for RTSL's Net Cash Flow are -$15412.0 (Q2 2023), $17572.0 (Q1 2023), and -$112164.0 (Q3 2022).